• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
TREAT-NMD

TREAT-NMD

Advancing diagnosis, care and treatment for people with neuromuscular diseases around the world

Contact us

header-right

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
  • What We Do
    • Advisory Committee for Therapeutics
    • The Global Registry Network
    • Core Datasets
    • Education
    • Post-Marketing Surveillance
  • Resources and Support
    • Neuromuscular Disease Information
    • Research Overview
    • Standards of Care & Family Guides
    • SOP Library
    • Social and Ethical Issues
  • Connect With Us
    • News
    • Events
    • Submit an Event
    • Newsletter Sign-up
    • Network Membership
    • Contact Us
    • Conference

Duchenne muscular dystrophy

Home / Resources and Support / Neuromuscular Disease Information / Duchenne muscular dystrophy

What is Duchenne muscular dystrophy?

Duchenne muscular dystrophy (DMD) is a genetic condition which causes progressive muscle degeneration and weakness. DMD is caused by mutations in the Dystrophin gene, and is one of four diseases known as the dystrophinopathies. The condition usually only affects males, and symptoms are usually observed in early childhood – typically between the ages of 2 and 3.

What causes Duchenne muscular dystrophy?

DMD is caused by a mutation in the gene called Dystrophin located on the X-chromosome. The mutation prevents the production of dystrophin protein, and its absence results in progressive muscle weakness as muscle cells break down and are gradually lost.

DMD is a genetic condition which can be inherited from the mother or be caused by a spontaneous mutation in a child’s genes (de novo mutation). As the dystrophin gene is on the X-chromosome, DMD almost only affects males (females have two X-chromosomes and the second copy can compensate for the faulty one). Females with one affected gene (called carriers) can pass the mutated gene to their children; Females with one affected gene (called carriers) can pass the mutated gene to their children; female carriers are at risk of developing heart problems and, therefore, should be monitored by a cardiologist.

What are the signs and symptoms of Duchenne muscular dystrophy?

The first signs and symptoms of DMD usually occur in early childhood: growth rate is typically slower than normal and those with DMD are usually late walkers. In toddlers, enlarged calf muscles may be evident due to abnormalities in muscle tissue.

Young children may have difficulty running, climbing stairs, and getting up from the floor to an upright position. When walking, affected boys may display a waddling gait and walk on their toes or the balls of their feet. Difficulties with balance and raising upper limbs may also be a sign of muscle weakness.

A lack of dystrophin can weaken the muscles that operate the lungs and diaphragm which can lead to respiratory issues and symptoms such as shortness of breath, headaches, and difficultly concentrating or staying awake. Children who use wheelchairs tend to have poor pulmonary function.

DMD causes heart problems including cardiomyopathy and conduction abnormalities. The heart should be closely monitored by a paediatric cardiologist as problems can occur without any symptoms.

Although serious cognitive disability is not common, boys with DMD may have some degree of learning disability affecting attention focusing, verbal learning and memory and/or emotional interaction. If a child is diagnosed with a learning disability, educational and psychological intervention can be put in place to support boys and their families.

How does the disease progress?

It is common for boys diagnosed with DMD to begin using a wheelchair by the age of 11. At first a wheelchair may only be used for long distances, however, later it is likely that affected boys will need to use a wheelchair full time.

As the disease progresses, muscle weakness means that maintaining a good posture is increasingly difficult, therefore, complications are more likely. DMD is a severe disease that shortens life expectancy, however, the high standards of care now available for patients means that many young men with DMD reach adulthood.

Primary Sidebar

  • Resources and Support
  • Disease Information
    • Neuromuscular Disease Information
    • Becker muscular dystrophy
    • Charcot-Marie-Tooth
    • Congenital muscular dystrophy
    • Congenital myasthenic syndromes
    • Duchenne muscular dystrophy
    • Facioscapulohumeral muscular dystrophy
    • GNE myopathy
    • Limb girdle muscular dystrophy
    • Myotonic dystrophy
    • Myotubular and centronuclear myopathies
    • Spinal muscular atrophy
  • Research Overview
    • Research Overview
    • Gene Therapy Research
    • DMD
      • DMD
      • Gene Therapy for DMD
      • Mutation Specific Approaches
      • Cell Therapy
      • Drug Therapy
  • Standards of Care & Family Guides
    • Care Guides
    • CM Care
    • CMD Care
    • DM Care
    • DMD Care
    • FSHD Care
    • SMA Care
  • Standard Operating Procedures (SOPs)
    • SOP Library
    • MDX Mouse (DMD)
    • GRMD Dog (DMD)
    • CMD Mouse (CMD)
    • SMA Mouse (SMA)
    • SOP Archive
      • MDX mouse (DMD) Archive
      • SMA mouse (SMA) Archive
      • Mouse model (DMD) Archive
  • Social and Ethical issues
    • Social and Ethical Issues
    • Concerns Over Stem Cell Therapy for SMA Type 1 Children
    • Early Access to Medicines in Development
    • Ethical Questions

Footer

Contact us

4th Floor
The Catalyst
Newcastle upon Tyne
NE4 5TG
United Kingdom
info@treat-nmd.com

Links

Home
Who we are
What we do
Who we support
Resources & support
Connect with us
Privacy Policy
Cookies

Newsletter Sign Up

Sign up to our monthly newsletter

Connect

info@treat-nmd.com
TREAT NMD © 2023
Privacy Policy
Sitemap
STCS LTD

  • Home
  • Who We Are
    • About Us
    • Partnerships and Collaborations
    • Governance
    • Our Team
    • Back
  • Who We Support
    • Patients
    • Clinicians / Researchers
    • Life Sciences Industry
    • Back
  • What We Do
    • Advisory Committee for Therapeutics
      • Members of the Advisory Committee for Therapeutics
      • Take Part in TACT
      • Past Applicants
      • Back
    • The Global Registry Network
      • Members of the Registry Network
      • Back
    • Core Datasets
      • DM dataset
      • DMD dataset
      • FSHD dataset
      • LGMD
      • SMA
      • Back
    • Education
      • Masterclasses
      • E-learning Platform
      • Endorsement of External Programmes
      • Back
    • Post-Marketing Surveillance
    • Back
  • Resources and Support
    • Neuromuscular Disease Information
      • Becker muscular dystrophy
      • Charcot-Marie-Tooth
      • Congenital muscular dystrophy
      • Congenital myasthenic syndromes
      • Duchenne muscular dystrophy
      • Facioscapulohumeral muscular dystrophy
      • GNE myopathy
      • Limb girdle muscular dystrophy
      • Myotonic dystrophy
      • Myotubular and centronuclear myopathies
      • Spinal muscular atrophy
      • Back
    • Research Overview
      • DMD
        • Gene Therapy for DMD
        • Mutation Specific Approaches
        • Cell Therapy
        • Drug Therapy
        • Back
      • Back
    • Standards of Care & Family Guides
      • CM Care
      • CMD Care
      • DM Care
      • DMD Care
      • FSHD Care
      • SMA Care
      • Back
    • SOP Library
      • MDX Mouse (DMD)
      • GRMD Dog (DMD)
      • CMD Mouse (CMD)
      • SMA Mouse (SMA)
      • CMD animal models
      • MDC1A Preclinical Research
      • Cell Lines
        • Clinical Outcome Measures
        • Functional Evaluation Tools
        • NMR (MRI/MRS) Imaging
        • Muscle Biopsy
        • Back
      • Back
    • Social and Ethical Issues
    • Back
  • Connect With Us
    • News
    • Events
    • Submit an Event
    • Newsletter Sign-up
    • Network Membership
    • Contact Us
    • Conference
    • Back